PA
₹334.75
+6.65(+2.03%)
PANACEABIO₹334.75+2.03%
Group Companies
Foreign Flows
sector level — not this stockHealthcare sector+₹3 Crnet foreign buying
2026-09-16 to 2026-09-endThis is the flow into the whole Healthcare sector, not into PANACEABIO. We report it at the level it is measured — attributing a sector figure to one company would be inventing a number nobody published.
Supply Chain
suppliers and customers in the graphMacro Sensitivity
rates, currency, commoditiesRevenue by Segment
Business Group
Geographic Exposure
revenue, imports, currencyScenario analysis
stated assumptions, shown workingsPANACEABIO exposure summary
In its latest segment disclosure (Mar 2026), Vaccines was the largest segment at 64.7% of segment revenue, followed by Formulations at 35.3%. Panacea Biotec Limited is a constituent of 2 indices.
| Index memberships | 2 |
|---|---|
| Largest segment | Vaccines · 64.7% |